Subscribe to RSS
Please copy the URL and add it into your RSS Feed Reader.
https://www.thieme-connect.de/rss/thieme/en/10.1055-s-00029029.xml
Download PDF
J Pediatr Intensive Care 2023; 12(02): 137-147
DOI: 10.1055/s-0041-1730932
DOI: 10.1055/s-0041-1730932
Original Article
Identification of Multisystem Inflammatory Syndrome in Children Classes and Development of Hyperinflammation Score in Pediatric COVID-19
Abstract
The aim of this study is to describe characteristics and hospital course of children admitted with COVID-19 to a tertiary care pediatric center in Southeastern United States, and to present the frequency of three classes of multisystem inflammatory syndrome in children (MIS-C) and develop pediatric COVID-19 associated hyperinflammation score (PcHIS). A retrospective cohort study of 68 children was performed. Critical illness was defined as any child requiring respiratory or cardiovascular support or renal replacement therapy. PcHIS was developed by using six variables: fever, hematological dysfunction, coagulopathy, hepatic injury, macrophage activation, and cytokinemia. Centers for Disease Control and Prevention criteria were used to identify MIS-C, and three classes of MIS-C were identified based on the findings of recently published latent class analysis (Class 1: MIS-C without Kawasaki like disease, Class 2: MIS-C with respiratory disease, and Class 3: MIS-C with Kawasaki like disease). The median age was 6.4 years. Fever, respiratory, and gastrointestinal were common presenting symptoms. MIS-C was present in 32 (47%), critical COVID-19 illness in 11 (16%), and 17 (25%) were admitted to the PICU. Children with critical illness were adolescents with elevated body mass index and premorbid conditions. PcHIS score of 3 had a sensitivity of 100% and a specificity of 77% for predicting critical COVID-19 illness. Among MIS-C patients, 15 (47%) were in Class 1, 8 (25%) were in Class 2, and 9 (28%) were in Class 3. We conclude that most children with COVID-19 have mild-to-moderate illness. Critical COVID-19 is mainly seen in obese adolescents with premorbid conditions. Three Classes of MIS-C are identifiable based on clinical features. Validation and clinical implication of inflammation score in pediatric COVID-19 need further investigation.
Publication History
Received: 22 March 2021
Accepted: 21 April 2021
Article published online:
19 June 2021
© 2021. Thieme. All rights reserved.
Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany
-
References
- 1 Castagnoli R, Votto M, Licari A. et al. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in children and adolescents: a systematic review. JAMA Pediatr 2020; 174 (09) 882-889
- 2 Belhadjer Z, Méot M, Bajolle F. et al. Acute heart failure in multisystem inflammatory syndrome in children (MIS-C) in the context of global SARS-CoV-2 pandemic. Circulation 2020;
- 3 Centers for Disease Control and Prevention. Information for Healthcare Providers about Multisystem Inflammatory Syndrome in Children. Case Definition for MIS-C.. 2020 . Accessed July 28, 2020 at: https://www.cdc.gov/mis-c/hcp/
- 4 Deza Leon MP, Redzepi A, McGrath E. et al. COVID-19-associated pediatric multisystem inflammatory syndrome. J Pediatric Infect Dis Soc 2020; 9 (03) 407-408
- 5 Dufort EM, Koumans EH, Chow EJ. et al; New York State and Centers for Disease Control and Prevention Multisystem Inflammatory Syndrome in Children Investigation Team. Multisystem inflammatory syndrome in children in New York State. N Engl J Med 2020; 383 (04) 347-358
- 6 Feldstein LR, Rose EB, Horwitz SM. et al; Overcoming COVID-19 Investigators, CDC COVID-19 Response Team. Multisystem inflammatory syndrome in U.S. children and adolescents. N Engl J Med 2020; 383 (04) 334-346
- 7 Riphagen S, Gomez X, Gonzalez-Martinez C, Wilkinson N, Theocharis P. Hyperinflammatory shock in children during COVID-19 pandemic. Lancet 2020; 395 (10237): 1607-1608
- 8 Shulman ST. Pediatric COVID-associated multi-system inflammatory syndrome (PMIS). J Pediatric Infect Dis Soc 2020;
- 9 Tezer H, Bedir Demirdağ T. Novel coronavirus disease (COVID-19) in children. Turk J Med Sci 2020; 50 (SI-1): 592-603
- 10 Verdoni L, Mazza A, Gervasoni A. et al. An outbreak of severe Kawasaki-like disease at the Italian epicentre of the SARS-CoV-2 epidemic: an observational cohort study. Lancet 2020; 395 (10239): 1771-1778
- 11 Centers for Disease Control and Prevention. Multisystem inflammatory syndrome in children (MIS-C) associated with coronavirus disease 2019 (COVID-19). 2020 . Accessed July 24, 2020 at: https://emergency.cdc.gov/han/2020/han00432.asp
- 12 Götzinger F, Santiago-García B, Noguera-Julián A. et al; ptbnet COVID-19 Study Group. COVID-19 in children and adolescents in Europe: a multinational, multicentre cohort study. Lancet Child Adolesc Health 2020; 4 (09) 653-661
- 13 Cheung EW, Zachariah P, Gorelik M. et al. Multisystem inflammatory syndrome related to COVID-19 in previously healthy children and adolescents in New York City. JAMA 2020; 324 (03) 294-296
- 14 Davies P, Evans C, Kanthimathinathan HK. et al. Intensive care admissions of children with pediatric inflammatory multisystem syndrome temporally associated with SARS-CoV-2 (PIMS-TS) in the UK: a multicentre observational study. Lancet Child Adolesc Health 2020; 4 (09) 669-677
- 15 Whittaker E, Bamford A, Kenny J. et al; PIMS-TS Study Group and EUCLIDS and PERFORM Consortia. Clinical characteristics of 58 children with a pediatric inflammatory multisystem syndrome temporally associated with SARS-CoV-2. JAMA 2020; 324 (03) 259-269
- 16 Levin M. Childhood multisystem inflammatory syndrome - a new challenge in the pandemic. N Engl J Med 2020; 383 (04) 393-395
- 17 Godfred-Cato S, Bryant B, Leung J. et al; California MIS-C Response Team. COVID-19-associated multisystem inflammatory syndrome in children - United States, March-July 2020. MMWR Morb Mortal Wkly Rep 2020; 69 (32) 1074-1080
- 18 Henry BM, Benoit SW, de Oliveira MHS. et al. Laboratory abnormalities in children with mild and severe coronavirus disease 2019 (COVID-19): a pooled analysis and review. Clin Biochem 2020; 81: 1-8
- 19 Schöning V, Liakoni E, Baumgartner C. et al. Development and validation of a prognostic COVID-19 severity assessment (COSA) score and machine learning models for patient triage at a tertiary hospital. J Transl Med 2021; 19 (01) 56
- 20 Goodacre S, Thomas B, Sutton L. et al. Derivation and validation of a clinical severity score for acutely ill adults with suspected COVID-19: The PRIEST observational cohort study. PLoS One 2021; 16 (01) e0245840
- 21 Webb BJ, Peltan ID, Jensen P. et al. Clinical criteria for COVID-19-associated hyperinflammatory syndrome: a cohort study. Lancet Rheumatol 2020; 2 (12) e754-e763
- 22 Lai CY, Tian L, Schisterman EF. Exact confidence interval estimation for the Youden index and its corresponding optimal cut-point. Comput Stat Data Anal 2012; 56 (05) 1103-1114
- 23 Kim L, Whitaker M, O'Halloran A. et al; COVID-NET Surveillance Team. Hospitalization rates and characteristics of children aged <18 years hospitalized with laboratory-confirmed COVID-19 - COVID-NET, 14 states, March 1-July 25, 2020. MMWR Morb Mortal Wkly Rep 2020; 69 (32) 1081-1088
- 24 Kanthimathinathan HK, Dhesi A, Hartshorn S. et al. COVID-19: a UK children's hospital experience. Hosp Pediatr 2020; 10 (09) 802-805
- 25 Liguoro I, Pilotto C, Bonanni M. et al. SARS-COV-2 infection in children and newborns: a systematic review. Eur J Pediatr 2020; 179 (07) 1029-1046
- 26 Aggarwal S, Garcia-Telles N, Aggarwal G, Lavie C, Lippi G, Henry BM. Clinical features, laboratory characteristics, and outcomes of patients hospitalized with coronavirus disease 2019 (COVID-19): Early report from the United States. Diagnosis (Berl) 2020; 7 (02) 91-96
- 27 Guan WJ, Ni ZY, Hu Y. et al; China Medical Treatment Expert Group for Covid-19. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med 2020; 382 (18) 1708-1720
- 28 Parri N, Lenge M, Buonsenso D. Coronavirus Infection in Pediatric Emergency Departments (CONFIDENCE) Research Group. Children with COVID-19 in pediatric emergency departments in Italy. N Engl J Med 2020; 383 (02) 187-190
- 29 Zachariah P, Johnson CL, Halabi KC. et al; Columbia Pediatric COVID-19 Management Group. Epidemiology, clinical features, and disease severity in patients with coronavirus disease 2019 (COVID-19) in a children's hospital in New York City, New York. JAMA Pediatr 2020; 174 (10) e202430
- 30 Ji M, Yuan L, Shen W. et al. A predictive model for disease progression in non-severely ill patients with coronavirus disease 2019. Eur Respir J 2020; 56 (01) 2001234
- 31 Su L, Ma X, Yu H. et al. The different clinical characteristics of corona virus disease cases between children and their families in China - the character of children with COVID-19. Emerg Microbes Infect 2020; 9 (01) 707-713
- 32 González-Dambrauskas S, Vásquez-Hoyos P, Camporesi A. et al; CRITICAL CORONAVIRUS AND KIDS EPIDEMIOLOGY CAKE STUDY. Pediatric critical care and COVID-19. Pediatrics 2020; 146 (03) e20201766
- 33 Tian Y, Rong L, Nian W, He Y. Review article: gastrointestinal features in COVID-19 and the possibility of faecal transmission. Aliment Pharmacol Ther 2020; 51 (09) 843-851
- 34 Riollano-Cruz M, Akkoyun E, Briceno-Brito E. et al. Multisystem inflammatory syndrome in children (MIS-C) related to COVID-19: a New York City Experience. J Med Virol 2020
- 35 Chiotos K, Bassiri H, Behrens EM. et al. Multisystem inflammatory syndrome in children during the coronavirus 2019 pandemic: a case series. J Pediatric Infect Dis Soc 2020; 9 (03) 393-398
- 36 Ouldali N, Pouletty M, Mariani P. et al. Emergence of Kawasaki disease related to SARS-CoV-2 infection in an epicentre of the French COVID-19 epidemic: a time-series analysis. Lancet Child Adolesc Health 2020; 4 (09) 662-668
- 37 Pouletty M, Borocco C, Ouldali N. et al. Paediatric multisystem inflammatory syndrome temporally associated with SARS-CoV-2 mimicking Kawasaki disease (Kawa-COVID-19): a multicentre cohort. Ann Rheum Dis 2020; 79 (08) 999-1006
- 38 Toubiana J, Poirault C, Corsia A. et al. Kawasaki-like multisystem inflammatory syndrome in children during the covid-19 pandemic in Paris, France: prospective observational study. BMJ 2020; 369: m2094
- 39 Frater JL, Zini G, d'Onofrio G, Rogers HJ. COVID-19 and the clinical hematology laboratory. Int J Lab Hematol 2020; 42 (Suppl. 01) 11-18
- 40 Huang I, Pranata R. Lymphopenia in severe coronavirus disease-2019 (COVID-19): systematic review and meta-analysis. J Intensive Care 2020; 8: 36
- 41 Tan L, Wang Q, Zhang D. et al. Lymphopenia predicts disease severity of COVID-19: a descriptive and predictive study. Signal Transduct Target Ther 2020; 5 (01) 33
- 42 Terpos E, Ntanasis-Stathopoulos I, Elalamy I. et al. Hematological findings and complications of COVID-19. Am J Hematol 2020; 95 (07) 834-847
- 43 Zhao Q, Meng M, Kumar R. et al. Lymphopenia is associated with severe coronavirus disease 2019 (COVID-19) infections: a systemic review and meta-analysis. Int J Infect Dis 2020; 96: 131-135
- 44 Chen R, Liang W, Jiang M. et al; Medical Treatment Expert Group for COVID-19. Risk factors of fatal outcome in hospitalized subjects with coronavirus disease 2019 from a nationwide analysis in china. Chest 2020; 158 (01) 97-105
- 45
Zhou F,
Yu T,
Du R.
et al.
Clinical course and risk factors for mortality of adult inpatients with COVID-19 in
Wuhan, China: a retrospective cohort study. Lancet 2020; 395 (10229): 1054-1062
MissingFormLabel